The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT: Long-term outcomes

Takuro Nishikawa, Jiro Inagaki, Yoshihisa Nagatoshi, Reiji Fukano, kentaro nakashima, Nobuhiro Ito, Daisuke Sawa, Yoshifumi Kawano, Jun Okamura

研究成果: Contribution to journalReview article査読

3 被引用数 (Scopus)

抄録

The impact of a second all-SCT on the long-term outcomes of children who relapse after allo-SCT has been unclear. We retrospectively analyzed the long-term outcomes of different salvage treatments for such children. Sixty-six children with hematological malignancies (40 ALL, 22 AML, three MDS, and one CML) who relapsed after a first allo-SCT received either a second allo-SCT (n = 16) or CTx and/or DLI (n = 50). The median follow-up for all children was 9.1 yr. The five-yr OS after relapse was significantly better in patients who underwent a second allo-SCT (42.9%) than in patients treated with CTx and/or DLI (11.8%) (p < 0.05). However, this advantage diminished with increasing time. The eight-yr OS for these groups of patients were 21.4% and 11.8%, respectively (p = n.s.). Among the 16 patients who received a second allo-SCT, two died more than five yr after the second allo-SCT. A second allo-SCT can therefore lead to a prolonged OS in patients who relapse after allo-SCT. However, a second allo-SCT should be selected carefully. This is because the mortality rate is still high, even when there is an extensive duration of time following the second allo-SCT.

本文言語英語
ページ(範囲)722-728
ページ数7
ジャーナルPediatric Transplantation
16
7
DOI
出版ステータス出版済み - 11 1 2012

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

フィンガープリント 「The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT: Long-term outcomes」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル